Prevalence of human papillomavirus (HPV) types 16 and 18 in cervical cancer in Stockholm, Sweden during 2019–2023 compared to 2003–2008

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi:10.1002/ijc.33588.
   Web of Science ®Google Scholar
• Engholm G, Ferlay J, Christensen N, et al. NORDCAN-a nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736. doi:10.3109/02841861003782017.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.socialstyrelsen.se/statistik-och-data/register/cancerregistret/
   Google Scholar
• Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 european countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677–686. doi:10.1158/1055–9965.EPI-04–0569.
   PubMed Web of Science ®Google Scholar
• Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 european countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–2199. doi:10.1158/1055–9965.EPI-05–0231.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265. doi:10.1136/jcp.55.4.244.
   PubMed Web of Science ®Google Scholar
• Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935. doi:10.1002/ijc.25396.
   PubMed Web of Science ®Google Scholar
• Barra F, Maggiore URL, Bogani G, et al. New prophylactic human papillomavirus (HPV) vaccines against cervical cancer. J Obstet Gynaecol. 2019;39(1):1–10. doi:10.1080/01443615.2018.1493441.
   PubMedGoogle Scholar
• Vänskä S, Söderlund-Strand A, Uhnoo I, et al. Estimating effectiveness of HPV vaccination against HPV infection from post- vaccination data in the absence of baseline data. Vaccine. 2018;36(23):3239–3246. doi:10.1016/j.vaccine.2018.04.073.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Pérez N, HPV Vaccination Impact Study Group., et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi:10.1016/S0140–6736(19)30298–3.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–1348. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Du J, Näsman A, Carlson JW, et al. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003–2008 in Stockholm, Sweden, before public HPV vaccination. Acta Oncol. 2011;50(8):1215–1219. doi:10.3109/0284186X.2011.584556.
   PubMed Web of Science ®Google Scholar
• Sivars L, Hellman K, Crona Guterstam Y, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer. Gynecol Oncol. 2022;167(1):107–114. doi:10.1016/j.ygyno.2022.07.028.
   PubMed Web of Science ®Google Scholar
• Hellman K, Hellström AC, Pettersson BF. Uterine cervix cancer treatment at radiumhemmet: 90 years’ experience. Time trends of age, stage, and histopathology distribution. Cancer Med. 2014;3(2):284–292. doi:10.1002/cam4.187.
   PubMed Web of Science ®Google Scholar
• Bjurberg M, Holmberg E, Borgfeldt C, et al. Primary treatment patterns and survival of cervical cancer in Sweden: a population-based swedish gynecologic cancer group study. Gynecol Oncol. 2019;155(2):229–236. doi:10.1016/j.ygyno.2019.08.022.
   PubMed Web of Science ®Google Scholar
• Usubutun A, Alemany L, Kucukali T, et al. Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol. 2009;28(6):541–548. doi:10.1097/PGP.0b013e3181aaba0d.
   PubMed Web of Science ®Google Scholar
• Carozzi FM, Tornesello ML, Burroni E, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2389–2400. doi:10.1158/1055–9965.EPI-10–0131.
   PubMed Web of Science ®Google Scholar
• Howell-Jones R, Bailey A, Beddows S, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer. 2010;103(2):209–216. doi:10.1038/sj.bjc.6605747.
   PubMed Web of Science ®Google Scholar
• Mariani L, Monfulleda N, Alemany L, et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer. 2010;10(1):259. doi:10.1186/1471–2407–10–259.
   PubMedGoogle Scholar